Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study.
Siebers AG, Arbyn M, Melchers WJ, van Kemenade FJ, Vedder JE, van der Linden H, van Ballegooijen M, Bekkers RL, Bulten J. Siebers AG, et al. Among authors: van der linden h, van kemenade fj, van ballegooijen m. Cancer Causes Control. 2014 Sep;25(9):1141-9. doi: 10.1007/s10552-014-0414-2. Epub 2014 Jun 17. Cancer Causes Control. 2014. PMID: 24935226
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.
Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, van den Brule AJ, Meijer CJ. Bulkmans NW, et al. Among authors: van den brule aj, van kemenade fj, van ballegooijen m. Int J Cancer. 2004 May 20;110(1):94-101. doi: 10.1002/ijc.20076. Int J Cancer. 2004. PMID: 15054873 Free article. Clinical Trial.
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs.
Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, Babović M, van Ballegooijen M, Helmerhorst TJ, Meijer CJ. Bais AG, et al. Among authors: van kemenade fj, van ballegooijen m. Int J Cancer. 2007 Apr 1;120(7):1505-10. doi: 10.1002/ijc.22484. Int J Cancer. 2007. PMID: 17205514 Free article. Clinical Trial.
The health and economic effects of HPV DNA screening in The Netherlands.
Berkhof J, Coupé VM, Bogaards JA, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, Meijer CJ. Berkhof J, et al. Among authors: van kemenade fj. Int J Cancer. 2010 Nov 1;127(9):2147-58. doi: 10.1002/ijc.25211. Int J Cancer. 2010. PMID: 20112339 Free article.
Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached?
de Kok IM, van der Aa MA, van Ballegooijen M, Siesling S, Karim-Kos HE, van Kemenade FJ, Coebergh JW; Working Group Output of the Netherlands Cancer Registry. de Kok IM, et al. Among authors: van der aa ma, van kemenade fj, van ballegooijen m. Int J Cancer. 2011 May 1;128(9):2174-81. doi: 10.1002/ijc.25553. Int J Cancer. 2011. PMID: 20626043 Free article.
Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women.
Overmeer RM, Louwers JA, Meijer CJ, van Kemenade FJ, Hesselink AT, Daalmeijer NF, Wilting SM, Heideman DA, Verheijen RH, Zaal A, van Baal WM, Berkhof J, Snijders PJ, Steenbergen RD. Overmeer RM, et al. Among authors: van baal wm, van kemenade fj. Int J Cancer. 2011 Nov 1;129(9):2218-25. doi: 10.1002/ijc.25890. Epub 2011 Mar 11. Int J Cancer. 2011. PMID: 21190187 Free article.
189 results